Back

Homology mediated end joining enables efficient non-viral targeted integration of large DNA templates in primary human T cells

Webber, B. R.; Johnson, M. J.; Slipek, N. S.; Lahr, W. S.; DeFeo, A. P.; Skeate, J. G.; Qiu, X.; Rathmann, B.; Diers, M. D.; Wick, B.; Henley, T.; Choudhry, M.; McIvor, R. S.; Moriarity, B. S.

2021-11-13 bioengineering
10.1101/2021.11.12.468427 bioRxiv
Show abstract

Adoptive cellular therapy using genetically engineered immune cells holds tremendous promise for the treatment of advanced cancers. While the number of available receptors targeting tumor specific antigens continues to grow, the current reliance on viral vectors for clinical production of engineered immune cells remains a significant bottleneck limiting translation of promising new therapies. Here, we describe an optimized methodology for efficient CRISPR-Cas9 based, non-viral engineering of primary human T cells that overcomes key limitations of previous approaches. By synergizing temporal optimization of reagent delivery, reagent composition, and integration mechanism, we achieve targeted integration of large DNA cargo at efficiencies nearing those of viral vector platforms with minimal toxicity. CAR-T cells generated using our approach are highly functional and elicit potent anti-tumor cytotoxicity in vitro and in vivo. Importantly, our method is readily adaptable to cGMP compliant manufacturing and clinical scale-up, offering a near-term alternative to the use of viral vectors for production of genetically engineered T cells for cancer immunotherapy.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.